Clene Nanomedicine to Present at Upcoming Investor Conferences

SALT LAKE CITY, March 03, 2022 (GLOBE NEWSWIRE) -- Clene Inc. CLNN along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Clene will participate in the following upcoming conferences:

• Roth 34^th Annual Healthcare Conference, March 14, 2022
  Presentation Time: 3:00 pm ET
  Webcast link: https://wsw.com/webcast/roth43/clnn/1822892

• Oppenheimer 32^nd Annual Healthcare Conference, March 15, 2022
  Presentation Time: 8:40 am ET
  Webcast link: https://wsw.com/webcast/oppenheimer20/clnn/2765322

• Maxim Group Emerging Growth Conference, March 28, 2022
  Presentation Time: 5:00 pm ET
  

Live audio webcasts will be available for on-demand viewing for the Roth and Oppenheimer Conferences and will be available on the Investors section of the company's website at www.clene.com. A replay will be available after the events and archived on the website for 90 days.

About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

Media Contact
Erica Fiorini, Ph.D., or David Schull
Russo Partners, LLC
Erica.fiorini@russopartnersllc.com
David.schull@russopartnersllc.com
+1-212-845-4253

Investor Contact
John Woolford
Managing Director, Westwicke
clene@westwicke.com
+1-443-213-0506